- Home
- Applications
- palestinian territories
- cancer cell
Show results for
Refine by
Cancer Cell Product Applications Available In Palestinian Territories
27 applications found
A non-invasive medical device, MarginProbe examines excised tissue during lumpectomy surgery and can detect the presence or absence of cancer cells on the margins. This provides vital, real time information to surgeons when it matters ...
ByDilon Technologies Inc. based in Newport News, VIRGINIA (USA)
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
ByAscelia Pharma AB based in Malmö, SWEDEN
One of the that cancer can be a serious disease is its ability to spread to other parts of the body beyond the location of the primary tumour. When cancer cells spread to distant lymph nodes, tissues or organs, it is called metastatic ...
ByAscelia Pharma AB based in Malmö, SWEDEN
Cancer is a group of diseases in which normal cells change and grow out of control. In breast cancer, the cancerous cells are usually cells of the lobules and ducts (ie, the glands that produce milk and the channels that carry milk to the nipple). Keep in mind that cancer, or carcinoma, of the breast can be broadly divided into two categories : ...
ByAurora Healthcare US Corp. based in Danvers, MASSACHUSETTS (USA)
The modular fashion with which Affilin® ligands can be fused together makes creating multi-specific binders an easy task. Combined with varying linker lengths, composition, and orientation, plus the optional addition of further accessory modules, our Navigo experts build the designed molecules as previously planned on the drawing ...
ByNavigo Proteins GmbH based in Halle, GERMANY
This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer).https://www.bocsci.com/ceritinib-cas-1032900-25-6-item-462148.html ...
ByAlfa Chemistry based in NY, NEW YORK (USA)
The development of highly cytotoxic drugs is needed for the success of the treatment in tumor cells. Paradoxically, the high toxicity limits its efficacy and application in vivo, causing damage to non-target organs and severe secondary effects. The use of directed liposomes has allowed the advance of many cancer drugs to preclinical and clinical trials, reducing side effects, and increasing their therapeutic index at the same time. More than 15 cancer liposomed ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Downregulating the immune response is necessary for the treatment of autoimmune diseases. In this aspect, the APO2L/TRAIL ligand is a key intermediate in immune cascades and is secreted in exosomes in natural conditions. Its alteration has been associated with rheumatoid arthritis. The administration of synthetic exosomes decorated with APO2L/TRAIL has been shown to be effective in reducing the hyperplasia and overall inflammation in this ...
ByNanovex Biotechnologies based in Llanera, SPAIN
NorthStar Medical Radioisotopes is poised to become the first-in-class supply chain for the future of therapeutic radiopharmaceuticals. Check back for progress on our non-carrier-added (n.c.a) Ac-225 and Cu-67 development ...
ByNorthStar Medical Radioisotopes, LLC based in Beloit, WISCONSIN (USA)
Cancer is one of the leading causes of deaths in India and a major public health concern. It is estimated that there are around 1 million new cancer cases every year and as many as 5 lakh deaths occur annually. Around 71% of all cancer deaths in India occur in people 30 to 69 years of age, when adults are very productive. The burden of cancer is expected to further increase due to increase in life expectancy, heavy use of tobacco and other risk factors such as radiation, viruses, ...
ByinDNA Research Labs based in , INDIA
Our product pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new mRNA vaccines and treatments that may have the potential to treat and prevent rare ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)
You need a complete answer to provide the best ...
ByBiocept based in San Diego, CALIFORNIA (USA)
IMMUNOSCORE® IC is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) ...
ByVeracyte based in Marseille Cedex 9, FRANCE
Comfortable and Efficient Compression Therapy Solutions . Lymphedema is swelling caused by a build-up of lymph fluid in the body. Lymph nodes are found throughout the body. Unfortunately, the lymph nodes near the breast can sometimes be affected by breast cancer treatment and cause the patient to develop lymphedema. Breast Cancer Related Lymphedema is usually related to axillary lymph node surgery and radiation therapy, but doctors and researchers still aren’t sure why some people get lymphedema and others ...
ByAIROS Medical Inc based in Audubon, PENNSYLVANIA (USA)
Using our platform, we are developing mRNA medicines for diverse uses and delivering them to patients across the globe. We are currently focusing on 4 medical areas - infectious diseases, immuno-oncology, rare diseases and autoimmune ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)
Randomized clinical trials (RCT’s) have been shown significant improvement in clinical outcome when hyperthermia was added to radiotherapy and/or chemotherapy. In 2004 experts in clinical hyperthermia held a consensus meeting (Kadota Fund International Forum 2004) about the evidence of the published clinical results of the RCT’s. Level 1 evidence was found for bladder cancer, breast cancer, cervical cancer, cancer of the esophagus, lymph nodes of head and neck tumors, rectum cancer, soft tissue ...
ByPyrexar based in Salt Lake City, UTAH (USA)
To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an assessment of the tumor immune response. ...
ByVeracyte based in Marseille Cedex 9, FRANCE
The increase or decrease of a natural immune response to obtain a therapeutic result is the basis of immunotherapy. It holds great promise for the treatment of autoimmune diseases, cancer, and the prevention of transplant ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Standard Biopsy Limitations Traditionally, men suspected of prostate cancer undergo systematic biopsies guided by ultrasound imaging. Because ultrasound offers poor cancer visualization, 12 random samples are taken without knowing if there is cancer and if so, where it is. As a result, the cancer is either missed entirely, or if detected, is difficult to determine the extent and severity. This leads to under treatment of men with serious disease and overtreatment of men with indolent disease.4 ...
ByFocal Healthcare based in Toronto, ONTARIO (CANADA)